Immunohistochemical analysis validated higher TBC1D1 expression levels in tumor tissues, and a substantial increase in TBC1D1 expression was observed in the glioma cell line, 1321N1 compared to the normal cell line HA1800 (Figures 2C–G). This evidence concerns the gene TBC1D1 and central nervous system cancer.